KalVista Pharmaceuticals creating a new generation of small molecule protease inhibitors for HAE and DME Hereditary Angioedema (HAE)Diabetic Macular Edema (DME)
News KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares Sep 10, 2018 KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock Sep 6, 2018 KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock Sep 5, 2018 All News
KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares Sep 10, 2018
